162358-48-7

Upstream product

• 111-14-8 oenanthic acid 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 2528-61-2 Heptanoic acid chloride 

Downstream Products

• 162358-49-8 N-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]phenyl]heptanamide 
• 162358-55-6 2-acetylamino-2-{2-[4-(heptyl-methyl-amino)-phenyl]-ethyl}-malonic acid diethyl ester 
• 162358-56-7 acetic acid 2-acetoxymethyl-2-acetylamino-4-[4-(heptyl-methyl-amino)-phenyl]-butyl ester 
• 1027989-08-7 N-{3-[4-(heptyl-methyl-amino)-phenyl]-1,1-bis-hydroxymethyl-propyl}-acetamide 
• 162358-50-1 N-methyl-N-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]phenyl]heptanamide 
• 162358-51-2 heptyl-methyl-{4-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-phenyl}-amine 
• 162358-53-4 methanesulfonic acid 2-[4-(heptyl-methyl-amino)-phenyl]-ethyl ester 
• 162358-54-5 4-(N-methylheptylamino)phenethyl iodide 
• 162358-52-3 4-(N-methylheptylamino)phenethyl alcohol 

Relevant academic research and scientific papers

Synthesis of novel FTY720 analogs with anticancer activity through PP2A activation

FTY720 inhibits various cancers through PP2A activation. The structure of FTY720 is also used as a basic structure for the design of sphingosine kinase (SK) inhibitors. We have synthesized derivatives using an amide chain in FTY720 with a phenyl backbone, and then compounds were screened by an MTT cell viability assay. The PP2A activity of compound 7 was examined. The phosphorylation levels of AKT and ERK, downstream targets of PP2A, in the presence of compound 7, were determined. Compound 7 may exhibit anticancer effects through PP2A activation rather than the mechanism by inhibition of SK1 in cancer cells. In the docking study of compound 7 and PP2A, the amide chain of compound 7 showed an interaction with Asn61 that was different from FTY720, which is expected to affect the activity of the compound.

Synthesis and immunosuppressive activity of 2-substituted 2- aminopropane-1,3-diols and 2-aminoethanols

A series of 2-substituted 2-aminopropane-1,3-diols was synthesized and evaluated for their lymphocyte-decreasing effect and immunosuppressive effect on rat skin allograft. A phenyl ring was introduced into the alkyl chain of the lead compound 3, which is an immunosuppressive agent structurally simplified from myriocin (1, ISP-I) via compound 2. The potency of the various compounds was dependent upon the position of the phenyl ring within the alkyl side chain. The most suitable length between the quaternary carbon atom and the phenyl ring was two carbon atoms. 2-Substituted 2-aminoethanols were successively synthesized and evaluated for their T-cell-decreasing effect and immunosuppressive effect using a popliteal lymph node gain assay in rats. The absolute configuration at the quaternary carbon affected the activity, and the (pro-S)-hydroxymethyl group of compound 6 was essential for potent immunosuppressive activity. Favorable substituents for the (pro-R)- hydroxymethyl group of 6 were hydroxyalkyl (hydroxyethyl and hydroxypropyl) or lower alkyl (methyl and ethyl) groups. 2-Amino-2-[2-(4- octylphenyl)ethyl]propane-1,3-diol hydrochloride (6, FTY720) was found to possess considerable activity and is expected to be useful as an immunosuppressive drug for organ transplantation.

2-amino-1,3-propanediol compound and immunosuppressant

2-Amino-1,3-propanediol compounds of the formula (I) STR1 wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R2, R3, R4 and R5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.